Genedata announces the multi-year expansion of its collaboration with Roche to include all Roche high throughput screening (HTS) facilities in North America and Europe.
Scientists at Roche use Genedata Screener® to estimate the biological potency of thousands of compounds as part of a their lead discovery workflow.
"We are pleased that Roche sees the value of our computational solutions for lead discovery", says Dr. Daniel Keesman, CEO of Genedata. Initiated originally at Roche's research facility in Basel, the collaboration has integrated Genedata's data quality evaluation and analysis workflow with Roche’s global screening infrastructure.
Roche has developed a unique process for screening entire compound libraries at multiple concentrations, a requirement for accurate potency estimation. Methods for analyzing compound potency tend to be time intensive and are difficult to standardize across entire compound libraries.
Genedata Screener® automates and standardizes potency estimation, enabling a genuinely high throughput workflow. “Screener has been deployed successfully at four major sites in a very short time period, assuring a return on the customer’s investment”, added Dr. Michael Lindemann, Business Head Genedata Screener. The system is based on an open and scalable architecture that enables tight IT integration without resource-intensive customization.